Connect with over 600 stroke nurses by exhibiting Virtually at AANN Advances in Stroke Care Conference.

Exhibit and Sponsorship Application

Maximize your opportunity! Join us at the International Neuroscience Nursing Research Symposium (INNRS) as well as the Stroke Conference.

For more information, contact Adrianne Stokes, Manager, Professional Relations & Development

The following Commercially Supported Symposia will be held during AANN’s Virtual Advances in Stroke Care Conference taking place Thursday, August 5-Saturday, August 7, 2021. Thank you to W. L. Gore & AstraZeneca Pharmaceuticals, LP for their support.


Thursday, August 5, 1-2 pm
PFO-Stroke Myths - Clarifying Common Misunderstandings about PFO and Stroke
Speaker: John J. Volpi, M.D

Supported by: W. L. Gore

Should shunt size influence whether or not you refer for closure? Is PFO closure only effective for younger patients? While there have been new published data on PFO closure to reduce the risk of recurrent stroke and guideline changes, there are still misunderstandings about who benefits from closure and how closure compares to other options. John J. Volpi, M.D., an internationally recognized vascular neurologist from Houston Methodist, will clarify the most common myths about PFO and stroke to deepen your knowledge on how this intervention can support better patient outcomes.

Friday, August 6, 7:25-8:25 am
Clinical Considerations in Stroke or Transient Ischemic Attack
Speaker: Carolyn Telford, MPAS, PA-C

Supported by: AstraZeneca Pharmaceuticals, LP

Learning Objectives:

  • Understand the disease burden and pathophysiology for acute ischemis stroke (AIS) and appreciate the underlying alterations in platelet physiology and phenotype in the context of AIS or high-risk transient ischemic attach (TIA).

  • Learn about the use of BRILINTA in patients with AIS and high-risk TIA and the differentiation of P2Y12 inhibitor use in this patient population

  • Appreciate the evidence and indications for BRILINTA across the spectrum of atherosclerotic and atherothrombotic disease by understanding the BRILINTA Pivotal Trials and the recently published THALES Trial.

Thank you to our past exhibitors/sponsors:



Arbor Pharmaceuticals, LLC



Christopher & Dana Reeve Foundation


Gore & Associates

National Institute of Neurological Disorders and Stroke (NINDS)

NeurOptics, Inc.

NIH- National Institute of Neurological Disorders & Stroke

Neurocritical Care Society